Publications by authors named "V Plante-Bordeneuve"
Article Synopsis
- The study focuses on transthyretin cardiac amyloidosis (ATTR-CM) as a significant cause of heart failure in older patients, analyzing how age and amyloidosis subtype affect patient outcomes.
- It included 943 patients, revealing that geriatric patients (≥75 years) had worse health outcomes and lower 3-year survival rates (55%) compared to non-geriatric patients (<75 years) who had a survival rate of 76%.
- Key mortality predictors differed by age group, with geriatric patients relying on alkaline phosphatase and troponin T levels, while non-geriatric patients linked outcomes to NT-proBNP and glomerular filtration rates; a new 3-stage prognostic
Background And Purpose: Peripheral neuropathy is a frequent complication of brentuximab vedotin (BV), used in CD30+ lymphoma treatment. Classic BV-induced neuropathy (BV-CN) is a mild distal sensory axonal polyneuropathy. Severe BV-induced inflammatory neuropathies (BV-IN) have been described.
View Article and Find Full Text PDFVutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy.
Expert Opin Drug Discov
April 2024
Introduction: Hereditary transthyretin (ATTRv) amyloidosis is a progressive, fatal disorder caused by mutations in the transthyretin (TTR) gene leading to deposition of the misfolded protein in amyloid fibrils. The main phenotypes are peripheral neuropathy (PN) and cardiomyopathy (CM).
Areas Covered: Gene silencing therapy, by dramatically reducing liver production of TTR, has transformed ATTRv-PN patient care in the last decade.
Article Synopsis
- Transthyretin amyloidosis (ATTR amyloidosis) has two forms: wild-type (ATTRwt) and hereditary (ATTRv), with over 130 identified genetic variants affecting patient symptoms.
- This analysis looked at four less common genetic variants (F64L, I68L, I107V, S77Y) in symptomatic patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS) to better understand their demographic and clinical characteristics.
- Findings revealed that most participants were older males, with distinct symptoms where F64L, I107V, and S77Y had more neurological issues, while I68L showed significant heart problems, highlighting the need for thorough patient evaluations across
Article Synopsis
- Transthyretin amyloidosis (ATTR amyloidosis) is a serious, progressive disease caused by the buildup of transthyretin amyloid fibrils in the body's tissues and organs, and can be hereditary or wild-type.* -
- The Transthyretin Amyloidosis Outcomes Survey (THAOS) is a major global study launched in 2007 that has tracked over 6,000 patients, including symptomatic patients and asymptomatic carriers, providing important data on the disease's characteristics.* -
- The recent analysis from THAOS revealed that most symptomatic patients are male, with a shift toward more mixed phenotypes and less predominantly cardiac phenotypes, highlighting the disease's complexity and variability among